Videos

Dr Mikhael reviews the baseline characteristics, study design and key efficacy and safety data of selinexor, carfilzomib, dexamethasone (XKd) in patients with relapsed/refractory multiple myeloma who are non-refractory to carfilzomib.

Joseph Mikhael, MD, provides a brief overview of the relapsed/refractory multiple myeloma landscape and explains the mechanism of action of selinexor.

Ursula A. Matulonis, MD, spoke about the motivation behind the phase 3 SORAYA trial investigating mirvetuximab soravtansine in patients with folate receptor α–high platinum-resistant ovarian cancer.

Insights on supportive care measures to minimize or counter common adverse effects for patients with R/R MM taking selinexor-based therapies

Closing out the program, Dr Ajay Nooka comments on the structural and biological disparities of care in multiple myeloma between Black and Caucasian patients, including age of presentation, delay of diagnosis and treatment, access to treatment options, and treatment response.

A look at some of the unmet needs in transplant-eligible multiple myeloma, particularly within the high-risk patient population.

Ajay Nooka, MD, and Matthew James Pianko, MD, discuss how they risk stratify patients with transplant-eligible multiple myeloma and the corresponding treatment approaches.

Discourse centered around dosing strategies for selinexor-based therapies.

Dr Caitlin Costello discusses how she adapts treatment to patients with transplant-ineligible NDMM based on fitness level, and why some patients receive doublet therapy.

Experts explain their approaches to maintenance therapy for patients with transplant-ineligible NDMM and when therapy should be reduced.

Dr Matthew James Pianko details how he determines treatment duration and discontinuation for transplant-eligible multiple myeloma.

Kevin Kalinsky, MD, MS, spoke about future studies following results from the phase 2 MAINTAIN trial of ribociclib with or without endocrine therapy and after progression on a CDK4/6 inhibitor for patients with unresectable or metastatic hormone receptor–positive, HER2-negative breast cancer.

Joseph Mikhael, MD, spoke about the mechanism of action of bispecific antibody teclistamab relative to other agents in the space such monoclonal antibodies and CAR T-cell therapies in multiple myeloma.

At 2022 IGCS, Lilian Gien, MD, spoke about a phase 2 trial which analyzed pembrolizumab plus epacadostat in patients with recurrent clear cell carcinoma of the ovary.

The MAINTAIN trial was designed to assess endocrine therapy with or without ribociclib after progression on a CDK4/6 inhibitor in patients with unresectable or metastatic hormone receptor–positive, HER2-negative breast cancer.

A breast cancer expert shares the current first-line standard of care for patients with HER2-positive breast cancer and presents scenarios where the standard treatment approach may not be appropriate.

Joyce O’Shaughnessy, MD shares an overview of the HER2-positive breast cancer landscape, focusing on prognosis and risk of recurrence for patients with early-stage and metastatic breast cancer.

Closing out their review of tazemetostat in R/R FL, participants consider its practical use in practice alongside other novel treatment modalities.

Dr Larry Anderson summarizes the study design and updated data of the MAIA trial, and Dr Rebecca Silbermann compares it against the SWOG 0777 trial.

Andrew Cowan, MD, presents the results of the ENDURANCE study comparing two triplet regimens in transplant-ineligible MM.

A brief review of both neoadjuvant and adjuvant treatment options available to patients with localized bladder cancer.

Opening their discussion on urothelial carcinoma management, panelists highlight risk factors, symptoms, and staging practices in this setting.

Tiffany Sia, MD, spoke about major takeaways from her study and how to implement procedural interventions for patients with gynecologic malignancies who have oligoprogression.

Two subject matter experts discuss keystone trials supporting the use of Selinexor in patients with R/R MM, each with unique dosing structures and different selinexor-based combinations.

Opening their discussion on relapsed/refractory multiple myeloma, Joshua Richter, MD and Peter Forsberg, MD review options for treatment sequencing, initiating treatment, and the mechanism of action for selinexor.

Data from the phase 3 ATHENA-MONO study indicated that maintenance rucaparib yielded progression-free survival benefit vs placebo across all subgroups in a population of patients newly diagnosed ovarian cancer, according to David O’Malley, MD.

At 2022 IGCS, Tiffany Sia, MD, spoke about using procedural interventions to treat patients with gynecologic malignancies who have oligoprogression on treatment with immune checkpoint inhibitors.

Caitlin Costello, MD, describes how to determine if a patient with MM is transplant-ineligible, and some factors to take into consideration when choosing a treatment regimen.

The panel explains their opinions on induction therapy approaches for high-risk and standard-risk patients with NDMM.

Drs Cheson and Park briefly review previous data from the E7438-G000-101 trial on tazemetostat in patients with wild-type or EZH2-mutant R/R FL, and then describe the findings of a more recent 2022 propensity score-matched analysis of the data that was intended to address baseline clinical differences between the two patient populations.